Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

926 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fc-GDF15 glyco-engineering and receptor binding affinity optimization for body weight regulation.
Fung E, Kang L, Sapashnik D, Benard S, Sievers A, Liu Y, Yan G, Zhou J, Rodriguez L, Ma W, Stochaj WR, LaVallie E, Wroblewska L, Kelleher K, Tam A, Bezy O, Breen D, Chabot JR, He T, Lin L, Wu Z, Mosyak L. Fung E, et al. Among authors: tam a. Sci Rep. 2021 Apr 26;11(1):8921. doi: 10.1038/s41598-021-87959-5. Sci Rep. 2021. PMID: 33903632 Free PMC article.
Mechanistic understanding of the cysteine capping modifications of antibodies enables selective chemical engineering in live mammalian cells.
Zhong X, He T, Prashad AS, Wang W, Cohen J, Ferguson D, Tam AS, Sousa E, Lin L, Tchistiakova L, Gatto S, D'Antona A, Luan YT, Ma W, Zollner R, Zhou J, Arve B, Somers W, Kriz R. Zhong X, et al. Among authors: tam as. J Biotechnol. 2017 Apr 20;248:48-58. doi: 10.1016/j.jbiotec.2017.03.006. Epub 2017 Mar 11. J Biotechnol. 2017. PMID: 28300660
Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.
Weng Y, Ishino T, Sievers A, Talukdar S, Chabot JR, Tam A, Duan W, Kerns K, Sousa E, He T, Logan A, Lee D, Li D, Zhou Y, Bernardo B, Joyce A, Kavosi M, O'Hara DM, Clark T, Guo J, Giragossian C, Stahl M, Calle RA, Kriz R, Somers W, Lin L. Weng Y, et al. Among authors: tam a. Sci Rep. 2018 Mar 9;8(1):4241. doi: 10.1038/s41598-018-22456-w. Sci Rep. 2018. PMID: 29523796 Free PMC article.
Transient CHO expression platform for robust antibody production and its enhanced N-glycan sialylation on therapeutic glycoproteins.
Zhong X, Ma W, Meade CL, Tam AS, Llewellyn E, Cornell R, Cote K, Scarcelli JJ, Marshall JK, Tzvetkova B, Figueroa B, DiNino D, Sievers A, Lee C, Guo J, Mahan E, Francis C, Lam K, D'Antona AM, Zollner R, Zhu HL, Kriz R, Somers W, Lin L. Zhong X, et al. Among authors: tam as. Biotechnol Prog. 2019 Jan;35(1):e2724. doi: 10.1002/btpr.2724. Epub 2018 Oct 27. Biotechnol Prog. 2019. PMID: 30299005
Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors.
Root AR, Guntas G, Katragadda M, Apgar JR, Narula J, Chang CS, Hanscom S, McKenna M, Wade J, Meade C, Ma W, Guo Y, Liu Y, Duan W, Hendershot C, King AC, Zhang Y, Sousa E, Tam A, Benard S, Yang H, Kelleher K, Jin F, Piche-Nicholas N, Keating SE, Narciandi F, Lawrence-Henderson R, Arai M, Stochaj WR, Svenson K, Mosyak L, Lam K, Francis C, Marquette K, Wroblewska L, Zhu HL, Sheehan AD, LaVallie ER, D'Antona AM, Betts A, King L, Rosfjord E, Cunningham O, Lin L, Sapra P, Tchistiakova L, Mathur D, Bloom L. Root AR, et al. Among authors: tam a. MAbs. 2021 Jan-Dec;13(1):1850395. doi: 10.1080/19420862.2020.1850395. MAbs. 2021. PMID: 33459147 Free PMC article.
Genetic rearrangement during site specific integration event facilitates cell line development of a bispecific molecule.
Tevelev B, Patel H, Shields K, Wei W, Cooley C, Zhang S, Bitzas G, Duan W, Khetemenee L, Jackobek R, D'Antona A, Sievers A, King A, Tam A, Zhang Y, Sousa E, Cohen J, Wroblewska L, Marshall J, Jackson M, Scarcelli JJ. Tevelev B, et al. Among authors: tam a. Biotechnol Prog. 2021 Jul;37(4):e3158. doi: 10.1002/btpr.3158. Epub 2021 May 12. Biotechnol Prog. 2021. PMID: 33891804 Free PMC article.
Impacts of fast production of afucosylated antibodies and Fc mutants in ExpiCHO-S™ for enhancing FcγRIIIa binding and NK cell activation.
Zhong X, Schenk J, Sakorafas P, Chamberland J, Tam A, Thomas LM, Yan G, D' Antona AM, Lin L, Nocula-Lugowska M, Zhang Y, Sousa E, Cohen J, Gu L, Abel M, Donahue J, Lim S, Meade C, Zhou J, Riegel L, Birch A, Fennell BJ, Franklin E, Gomes JM, Tzvetkova B, Scarcelli JJ. Zhong X, et al. Among authors: tam a. J Biotechnol. 2022 Dec 10;360:79-91. doi: 10.1016/j.jbiotec.2022.10.016. Epub 2022 Oct 27. J Biotechnol. 2022. PMID: 36341973 Free article.
926 results